Mani Subramanian
Investing Profile
Sweet spot: $25M
Range: $10M–$100M
Fund: $310.1M
Samsara BioCapital thesis
Dr. Thomas is a physician scientist, immunologist with more than 20 years of experience in academia, large pharmaceutical companies and biotech across multiple diverse therapeutic areas. She has been a venture partner at Samsara BioCapital since 2023 and is currently an independent board director for Allakos Therapeutics and Ventus Therapeutics. She is also a scientific advisor for AnaptysBio. Prior to Samsara, she was a board director for Chinook (acquired by Novartis in 2023) and held multiple roles in biotech companies including Executive Vice President, Head of Research and Development and
Sector and stage focus
- Seed: BioTech, Health IT, Digital Health, Health & Hospital Services
- Series A: BioTech, Health IT, Health & Hospital Services, Digital Health
- general: San Francisco Bay Area
Is Mani Subramanian a fit for your round?
Upload your pitch deck and see whether Mani Subramanian appears in your top 20 matches.
Find investors for your deck